S0718: Phase I Study Evaluating The Combination of GW786034 (Pazopanib; NSC-737754; IND-XXXX) and CCI-779 (Temsirolimus; NSC-683864; IND-XXXX) in Patients With Advanced Solid Tumors
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Temsirolimus (Primary) ; Pazopanib
- Indications Solid tumours
- Focus Adverse reactions
- 30 Jan 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 26 Nov 2008 New trial record.